← Ablatotech Vitals
Rheumatology EvidenceDigest

Efficacy of Novel Therapies for Managing Enthesitis in Psoriatic Arthritis

Rheumatology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 26, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Novel therapies targeting key inflammatory pathways have expanded treatment options for enthesitis in psoriatic arthritis (PsA), a major contributor to morbidity. Biologic agents including IL-17 and IL-23 inhibitors, as well as T-cell co-stimulation modulators like abatacept, demonstrate efficacy in reducing enthesitis severity. Adjunctive strategies such as weight loss may further improve outcomes. However, heterogeneity in assessment methods and patient response necessitate individualized treatment plans and further research to optimize management.

Clinical bottom line

Novel therapies targeting key inflammatory pathways have expanded treatment options for enthesitis in psoriatic arthritis (PsA), a major contributor to morbidity. Biologic agents including IL-17 and IL-23 inhibitors, as well as T-cell co-stimulation modulators like abatacept, demonstrate efficacy in reducing enthesitis severity. Adjunctive strategies such as weight loss may further improve outcomes. However, heterogeneity in assessment methods and patient response necessitate individualized treatment plans and further research to optimize management.

What the evidence shows

Enthesitis, inflammation at tendon and ligament insertion sites, is a hallmark of PsA and correlates with disease activity and functional impairment. Mease et al. (2011) provide validated measures for enthesitis assessment, including the Leeds Enthesitis Index (LEI) and Spondyloarthritis Research Consortium of Canada (SPARCC) index, facilitating standardized evaluation in clinical trials and practice.

Arraf et al. (2025) review novel pharmacotherapies in PsA, highlighting IL-17 inhibitors (secukinumab, ixekizumab) and IL-23 inhibitors (guselkumab) as effective in reducing enthesitis. These agents target cytokines central to PsA pathogenesis, with clinical trials demonstrating significant improvements in enthesitis scores and patient-reported outcomes.

Noisette et al. (2018) discuss abatacept, a selective T-cell co-stimulation modulator, which has shown efficacy in PsA patients with enthesitis, particularly those with inadequate response to TNF inhibitors. Patient selection based on immunophenotyping may optimize abatacept use.

Williams et al. (2024) emphasize the role of metabolic syndrome and obesity in PsA severity, noting that weight loss acts as a disease-modifying intervention that can reduce enthesitis and overall inflammation, complementing pharmacologic therapies.

Ultrasound imaging enhances detection and monitoring of enthesitis, as reported in a 2019 case medical research study, enabling objective assessment of treatment response.

Shenoi et al. (2024) provide insights from juvenile idiopathic arthritis treatment paradigms, underscoring the importance of early intervention and targeted therapies to prevent enthesitis-related damage.

D’Aprile et al. (2014) describe MRI features of enthesitis in PsA, supporting imaging as an adjunct to clinical evaluation.

Caveats and uncertainty

Variability in enthesitis scoring systems and lack of consensus on optimal assessment tools limit comparability across studies.

Long-term comparative effectiveness data for newer biologics in enthesitis are sparse.

Response heterogeneity necessitates biomarkers or clinical predictors to guide therapy selection.

Weight loss interventions require integration into multidisciplinary care but may face adherence challenges.

Imaging modalities, while informative, may not be universally accessible.

How this may change practice

Clinicians should incorporate validated enthesitis indices and imaging to accurately assess and monitor enthesitis in PsA.

IL-17 and IL-23 inhibitors represent effective options for patients with refractory enthesitis, with abatacept as a potential alternative in selected cases.

Addressing metabolic comorbidities through weight management may enhance therapeutic response.

Personalized treatment strategies combining pharmacologic and lifestyle interventions may optimize outcomes.

Ongoing research into biomarkers and standardized assessment tools will refine enthesitis management.


References

  1. Arraf A, et al. Novel pharmacotherapies and breakthroughs in psoriatic arthritis treatment. Expert Opin Pharmacother. 2025;26(4):345-359. DOI:10.1080/14656566.2025.2601050
  2. Mease PJ, et al. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT‐F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S64-85. DOI:10.1002/acr.20577
  3. Noisette A, et al. Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives. Psoriasis (Auckl). 2018;8:1-9. DOI:10.2147/PTT.S146076
  4. Williams JC, et al. Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy. Ther Adv Musculoskelet Dis. 2024;16:1759720X241271886. DOI:10.1177/1759720X241271886
  5. Shenoi S, et al. Treatment of non-systemic juvenile idiopathic arthritis. Nat Rev Rheumatol. 2024;20(3):145-160. DOI:10.1038/s41584-024-01079-8
  6. D’Aprile P, et al. Psoriatic Arthritis. MRI of Rheumatic Spine. 2014;41:345-360. DOI:10.1007/978-3-319-05627-2_41
  7. D’Aprile P, et al. Psoriatic Arthritis. MRI of Rheumatic Spine. 2014;45:400-415. DOI:10.1007/978-3-319-05627-2_45
  8. [Anonymous]. Ultrasound Enthesitis Response in Psoriatic Arthritis. Case Med Res. 2019;7(2):123-130. DOI:10.31525/ct1-nct03955861

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team